Last reviewed · How we verify

NCT06860373

LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD)

Terminated Phase 3 Last updated 6 March 2025
What this trial tests

Phase 3 trial testing [18F]MK-6240 in Down Syndrome in 5 participants. Terminated before completion.

Timeline
27 June 2023
Primary endpoint
17 April 2024
17 April 2024

Quick facts

Lead sponsorLuMind IDSC Foundation
PhasePhase 3
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment5
Start date27 June 2023
Primary completion17 April 2024
Estimated completion17 April 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

LuMind IDSC Foundation

Who can join

Adults 35 to 55, any sex, with Down Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an optional sub-study that will enroll participants from the LIFE-DSR parent protocol. Participants will undergo assessments at two timepoints, including: additional blood samples for PBMC and RNA extraction, as well as a lumbar puncture for collection of CSF, and/or MRI and tau PET imaging. Sub-study visits will be scheduled around a similar calendar-day as the parent protocol study visits (e.g., Month (M) 0 (M0) and M16, or M16 and M32).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of [18F]MK-6240

Trials testing the same drug.

Other recruiting trials for Down Syndrome

Currently open trials in the same condition.

Other LuMind IDSC Foundation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860373.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing